

Supplementary Documents [IFRS]

Financial results for the fiscal year 2021 (FY2021)

Astellas Pharma Inc.

- FY2021 Financial Results
 - For the year ended March 31, 2022
 - Three months ended March 31, 2022
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31, 2022]

1. Consolidated Results (Full Basis)

	Unit: B¥				Forecasts		Forecasts		Change from FY21	
	FY20 Full Year	FY21 Full Year	Change	Change (%)	FY21 Full Year	FY22 Full Year	Change (%)			
Revenue	1,249.5	1,296.2	46.6	3.7%	1,323.0	1,443.0	11.3%			
Cost of sales	246.1	253.0	6.9	2.8%						
Ratio to Revenue	19.7%	19.5%								
Gross profit	1,003.5	1,043.2	39.7	4.0%						
SG&A expenses	504.3	548.8	44.5	8.8%	541.0	598.0	9.0%			
Ratio to Revenue	40.4%	42.3%			40.9%	41.4%				
XTANDI co-promotion fee in the United states	120.2	139.3	19.1	15.9%		182.0	30.6%			
Personnel expenses	182.2	191.4	9.2	5.0%						
Advertising and Sales Promotion and Other	201.9	218.1	16.2	8.0%						
R&D expenses	224.5	246.0	21.5	9.6%	242.0	254.0	3.2%			
Ratio to Revenue	18.0%	19.0%			18.3%	17.6%				
Amortisation of intangible assets	23.8	28.3	4.5	19.0%						
Gain on divestiture of intangible assets	-	24.2	24.2	-						
Share of profit (loss) of investments accounted for using equity method	0.5	0.5	0.0	2.2%						
Other income	7.6	15.3	7.6	99.7%						
Net foreign exchange gains	-	8.2	8.2	-						
Fair value remeasurements on contingent consideration	3.6	5.4	1.8	49.5%						
Other expense	123.0	104.3	-18.6	-15.2%						
Impairment losses	101.7	74.9	-26.9	-26.4%						
Restructuring costs	9.3	19.6	10.3	110.4%						
Net foreign exchange losses	2.3	-	-2.3	-100.0%						
Fair value remeasurements on contingent consideration	6.0	7.0	1.0	17.4%						
Operating profit	136.1	155.7	19.6	14.4%	218.0	269.0	72.8%			
Ratio to Revenue	10.9%	12.0%			16.5%	18.6%				
Finance income	11.6	6.1	-5.5	-47.0%						
Finance expenses	2.3	4.9	2.6	112.0%						
Profit before tax	145.3	156.9	11.6	8.0%	216.0	267.0	70.2%			
Ratio to Revenue	11.6%	12.1%			16.3%	18.5%				
Income tax expense	24.7	32.8	8.1	32.6%						
Profit	120.6	124.1	3.5	2.9%	174.0	208.0	67.6%			
Ratio to Revenue	9.7%	9.6%			13.1%	14.4%				
Comprehensive income	181.5	208.1	26.6	14.7%						

2. Consolidated Results (Core Basis)

Unit: B¥

	FY20 Full Year	FY21 Full Year	Change	Change (%)
Revenue	1,249.5	1,296.2	46.6	3.7%
Cost of sales	246.1	253.0	6.9	2.8%
Ratio to Revenue	19.7%	19.5%		
Gross profit	1,003.5	1,043.2	39.7	4.0%
SG&A expenses	504.3	548.8	44.5	8.8%
Ratio to Revenue	40.4%	42.3%		
XTANDI co-promotion fee in the United states	120.2	139.3	19.1	15.9%
Personnel expenses	182.2	191.4	9.2	5.0%
Advertising and Sales Promotion and Other	201.9	218.1	16.2	8.0%
R&D expenses	224.5	246.0	21.5	9.6%
Ratio to Revenue	18.0%	19.0%		
Gain on divestiture of intangible assets	23.8	28.3	4.5	19.0%
Amortisation of intangible assets	-	24.2	24.2	-
Share of profit (loss) of investments accounted for using equity method	0.5	0.5	0.0	2.2%
Operating profit	251.4	244.7	-6.6	-2.6%
Ratio to Revenue	20.1%	18.9%		
Finance income	11.6	6.1	-5.5	-47.0%
Finance expenses	2.3	4.9	2.6	112.0%
Profit before tax	260.6	245.9	-14.7	-5.6%
Ratio to Revenue	20.9%	19.0%		
Income tax expense	50.7	55.4	4.6	9.1%
Profit	209.9	190.6	-19.3	-9.2%
Ratio to Revenue	16.8%	14.7%		

Forecasts

FY21 Full Year
1,323.0
541.0
40.9%
242.0
18.3%
270.0
20.4%
213.0
16.1%

Change from
FY21

Forecasts	Change from FY21
FY22 Full Year	Change (%)
1,443.0	11.3%
598.0	9.0%
41.4%	
182.0	30.6%
254.0	3.2%
17.6%	
290.0	18.5%
20.1%	
223.0	17.0%
15.5%	

3. Exchange Rate

Unit: yen

	FY20 Ave.	FY21 Ave.	FY20 End	FY21 End
USD/Yen	106	112	111	122
EUR/Yen	124	131	130	135

Forecasts

FY21 Full Year
110
130

Forecasts

FY22 Full Year
120
135

* Fx impacts: Revenue +59.6 billion yen and Core operating profit +18.5 billion yen

* Fx impact on elimination of unrealized gain: COGs ratio +0.2ppt

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY20 Full year			FY21 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	1,249.5	-	1,249.5	1,296.2	-	1,296.2
Cost of sales	246.1	-	246.1	253.0	-	253.0
Gross profit	1,003.5	-	1,003.5	1,043.2	-	1,043.2
SG&A expenses	504.3	-	504.3	548.8	-	548.8
R&D expenses	224.5	-	224.5	246.0	-	246.0
Amortisation of intangible assets	23.8	-	23.8	28.3	-	28.3
Gain on divestiture of intangible assets	-	-	-	24.2	-	24.2
Share of profit (loss) of investments accounted for using equity method	0.5	-	0.5	0.5	-	0.5
Other income *	7.6	-7.6	-	15.3	-15.3	-
Other expenses *	123.0	-123.0	-	104.3	-104.3	-
Operating profit	136.1	115.3	251.4	155.7	89.1	244.7
Finance income	11.6	-	11.6	6.1	-	6.1
Finance expenses	2.3	-	2.3	4.9	-	4.9
Profit before tax	145.3	115.3	260.6	156.9	89.1	245.9
Income tax expense	24.7	26.0	50.7	32.8	22.6	55.4
Profit	120.6	89.3	209.9	124.1	66.5	190.6

* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

		Unit: B¥			
		FY20 Full Year	FY21 Full Year	Change	Change (%)
Revenue		1,249.5	1,296.2	46.6	3.7%
	Japan	279.1	258.8	-20.4	-7.3%
	Ratio to Revenue	22.3%	20.0%		
	United States	473.2	537.5	64.3	13.6%
	Ratio to Revenue	37.9%	41.5%		
	Established Markets	293.2	315.2	22.0	7.5%
	Ratio to Revenue	23.5%	24.3%		
	Greater China	59.3	66.3	7.0	11.8%
	Ratio to Revenue	4.7%	5.1%		
	International Markets	111.1	110.1	-1.0	-0.9%
	Ratio to Revenue	8.9%	8.5%		
	Others	33.6	8.4	-25.2	-75.0%
	Ratio to Revenue	2.7%	0.6%		

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc

		Forecasts		Change from FY21	
		FY21 Full Year	FY22 Full Year	FY21 Full Year	FY22 Full Year
		1,323.0	1,443.0		11.3%
		252.1	260.0		0.5%
		19.0%	18.0%		
		552.5	644.2		19.9%
		41.8%	44.6%		
		322.1	339.9		7.8%
		24.3%	23.6%		
		65.0	74.4		12.2%
		4.9%	5.2%		
		122.5	118.5		7.7%
		9.3%	8.2%		
		8.9	6.0		-28.1%
		0.7%	0.4%		

6. Per Share Information

	FY20 Full Year	FY21 Full Year
The number of shares issued (thousand)	1,861,787	1,835,852
Treasury Shares (thousand)	8,758	8,778
The number of shares issued after deducting Treasury Shares (thousand)	1,853,029	1,827,074
Earnings per share (yen)	64.93	67.08
Earnings per share (yen) core basis	113.03	103.03
Dividend per share (yen)	42	50
Return on Equity (%)	9.0%	8.7%
Dividend on Earnings (%)	5.8%	6.5%

Forecasts		Forecasts	
FY21 Full Year		FY22 Full Year	
	93.90		113.84
	114.95		122.05
	50		60

7. Investment in Property, Plant and Equipment Depreciation/Amortisation

		Unit: B¥			
		FY20 Full Year	FY21 Full Year	Change	Change (%)
Investment in Property, Plant and Equipment					
	Consolidated	33.7	30.2	-3.5	-10.5%
Depreciation (PP&E)					
	Consolidated	40.0	40.1	0.1	0.2%
Amortisation of Intangible Assets (incl. software, etc.)					
	Consolidated	32.7	39.6	7.0	21.3%

- Investment in Property, Plant and Equipment does not include right-of-use asset

		Forecasts		Change from FY21	
		FY21 Full Year	FY22 Full Year	FY21 Full Year	FY22 Full Year
		34.0	39.0		29.3%
		42.0	40.0		-0.1%
		38.0	42.0		6.0%

8. Sales of major products

1) Global

		Unit: B¥				Forecasts		Change from FY21	
		FY20 Full Year	FY21 Full Year	Change	Change (%)	FY21 Full Year	FY22 Full Year	Change (%)	
XTANDI		458.4	534.3	75.9	16.6%	554.1	642.5	20.3%	
	United States	238.6	276.9	38.3	16.1%	290.2	353.9	27.8%	
	ex-US	219.8	257.4	37.6	17.1%	264.0	288.6	12.1%	
	Japan	40.2	47.2	7.0	17.3%	47.1	52.6	11.4%	
	Established Markets	149.3	170.1	20.8	13.9%	176.0	182.1	7.1%	
	Greater China	4.9	7.9	3.0	62.0%	8.2	13.3	67.5%	
	International Markets	25.5	32.2	6.7	26.5%	32.6	40.6	26.1%	
XOSPATA		23.8	34.1	10.2	42.9%	35.4	46.2	35.5%	
	Japan	3.8	3.9	0.1	3.2%	4.4	4.9	26.0%	
	United States	15.5	18.9	3.4	21.9%	19.2	25.2	33.4%	
	Established Markets	4.4	9.0	4.7	105.8%	9.4	11.8	30.6%	
	Greater China	0.0	1.5	1.5	-	1.7	2.4	54.0%	
	International Markets	0.2	0.7	0.5	348.5%	0.6	1.9	173.5%	
PADCEV		12.8	21.7	8.9	69.5%	20.7	36.5	68.0%	
	Japan	-	1.8	1.8	-	0.8	4.3	146.7%	
	United States	12.8	19.5	6.7	52.2%	19.7	27.6	41.4%	
	Established Markets	-	0.5	0.5	-	0.2	4.6	891.8%	
EVRENZO		1.1	2.6	1.5	131.5%	7.2	9.9	281.2%	
	Japan	1.1	2.5	1.4	121.8%	4.1	6.3	152.6%	
	Established Markets	-	0.1	0.1	-	3.2	3.4	-	
Betanis/Myrabetriq/BETMIGA		163.6	172.3	8.7	5.3%	176.3	178.7	3.7%	
	Japan	35.1	37.5	2.4	6.9%	36.7	36.2	-3.5%	
	United States	88.0	87.2	-0.8	-0.9%	93.0	90.2	3.5%	
	Established Markets	29.9	36.7	6.8	22.7%	35.7	40.6	10.9%	
	Greater China	2.2	2.9	0.7	33.4%	2.7	3.6	21.8%	
	International Markets	8.5	8.1	-0.4	-5.0%	8.2	8.1	0.0%	
Vesicare		31.6	22.0	-9.7	-30.6%	18.9	12.7	-42.0%	
	Japan	18.5	10.0	-8.5	-45.9%	7.6	1.8	-82.4%	
	United States	2.2	1.7	-0.5	-23.9%	1.5	1.3	-20.2%	
	Established Markets	6.2	5.5	-0.7	-11.9%	5.2	4.8	-13.3%	
	Greater China	1.0	1.0	0.0	1.0%	1.0	1.0	-5.8%	
	International Markets	3.7	3.7	-0.0	-0.2%	3.6	3.9	5.1%	
Prograf		182.7	185.4	2.7	1.5%	185.7	190.7	2.9%	
	Japan	40.7	38.2	-2.5	-6.2%	38.2	35.7	-6.6%	
	United States	11.8	9.4	-2.4	-20.6%	9.1	10.4	10.4%	
	Established Markets	64.2	67.9	3.7	5.8%	67.3	69.9	2.9%	
	Greater China	34.2	38.1	3.9	11.5%	37.9	41.3	8.3%	
	International Markets	31.7	31.7	0.0	0.1%	33.2	33.5	5.4%	

- Sales of products in Japan are shown in a gross sales basis

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY20 Full Year	FY21 Full Year	Change	Change (%)
XTANDI	40.2	47.2	7.0	17.3%
XOSPATA	3.8	3.9	0.1	3.2%
PADCEV	-	1.8	1.8	-
EVRENZO	1.1	2.5	1.4	121.8%
Betanis	35.1	37.5	2.4	6.9%
Vesicare	18.5	10.0	-8.5	-45.9%
Prograf (Including Graceptor)	40.7	38.2	-2.5	-6.2%
Harnal	3.0	2.6	-0.4	-14.0%
Funguard	4.4	1.6	-2.8	-63.0%

Forecasts FY21 Full Year
47.1
4.4
0.8
4.1
36.7
7.6
38.2
2.4
1.5

Forecasts FY22 Full Year	Change from FY21 (%)
52.6	11.5%
4.9	26.0%
4.3	146.7%
6.3	152.6%
36.2	-3.5%
1.8	-82.4%
35.7	-6.6%
1.4	-45.3%
0.9	-46.6%

<Main products>

Suglat [Family]	27.9	30.3	2.4	8.4%
Sujanu	11.3	12.5	1.1	10.1%
Repatha	5.1	5.8	0.7	12.8%
Linzess	6.4	6.9	0.5	8.6%
BLINCYTO	4.5	6.4	1.8	40.1%
EVENITY	24.8	31.4	6.6	26.6%
Smyraf	1.7	2.4	0.7	42.5%
Geninax	2.5	2.6	0.1	3.7%
Vaccines	7.9	5.1	-2.8	-35.1%
Gonax	5.1	5.0	-0.1	-1.4%
Cimzia	10.0	11.2	1.1	11.2%
Myslee	7.8	7.0	-0.8	-10.1%
Total Rx Sales In Japanese market	276.6	256.9	-19.6	-7.1%

30.5
7.0
3.1
3.1
5.2
5.0
6.9
250.3

33.1	9.3%
7.8	12.8%
3.3	39.1%
8.6	67.7%
4.9	-1.3%
5.5	-22.3%
257.5	0.2%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M\$

	FY20 Full Year	FY21 Full Year	Change	Change (%)
Revenue	4,462	4,782	320	7.2%
XTANDI	2,250	2,464	214	9.5%
XOSPATA	146	168	22	15.1%
PADCEV	121	174	53	43.7%
Myrbetriq	829	775	-54	-6.5%
Vesicare	20	15	-6	-28.2%
Prograf	112	84	-28	-25.1%
MYCAMINE	83	48	-35	-41.9%
AmBisome	114	135	21	18.5%
CRESEMBA	160	194	35	21.8%
Lexiscan	623	725	103	16.5%

Forecasts

FY21 Full Year
5,022
2,638
175
179
845
13
83
45
127
185
732

Forecasts
Change from
FY21

FY22 Full Year	Change (%)
5,368	12.3%
2,949	19.7%
210	24.9%
230	32.4%
752	-3.1%
11	-25.3%
87	3.4%
18	-62.5%
143	6.2%
209	7.4%
739	1.9%

(3) Established Markets

Unit: M€

	FY20 Full Year	FY21 Full Year	Change	Change (%)
Revenue	2,370	2,414	44	1.9%
XTANDI	1,207	1,303	96	8.0%
XOSPATA	36	69	34	95.0%
PADCEV	-	4	4	-
EVRENZO	-	1	1	-
BETMIGA	241	281	39	16.3%
Vesicare	50	42	-8	-16.5%
Prograf	519	520	1	0.3%
Omnice	65	67	2	3.6%
MYCAMINE	45	22	-23	-51.6%

Forecasts

FY21 Full Year
2,477
1,354
73
1
24
275
40
518
65
23

Forecasts
Change from
FY21

FY22 Full Year	Change (%)
2,517	4.3%
1,349	3.5%
88	26.3%
34	859.1%
25	-
301	7.2%
35	-16.1%
518	-0.4%
64	-5.2%
15	-29.0%

- Established Markets: Europe, Canada, Australia

(4) Greater China

	Unit: B¥			
	FY20 Full Year	FY21 Full Year	Change	Change (%)
Revenue	59.3	66.3	7.0	11.8%
XTANDI	4.9	7.9	3.0	62.0%
XOSPATA	0.0	1.5	1.5	-
BETMIGA	2.2	2.9	0.7	33.4%
Vesicare	1.0	1.0	0.0	1.0%
Prograf	34.2	38.1	3.9	11.5%
Harnal	10.8	8.2	-2.6	-24.4%
MYCAMINE	2.5	2.9	0.4	17.9%
Feburic	2.6	2.9	0.3	9.7%

- Greater China: China, Hong Kong, Taiwan

Forecasts		Change from FY21	
FY21 Full Year	FY22 Full Year	FY22 Full Year	Change (%)
65.0	74.4	74.4	12.2%
8.2	13.3	13.3	67.5%
1.7	2.4	2.4	54.0%
2.7	3.6	3.6	21.8%
1.0	1.0	1.0	-5.8%
37.9	41.3	41.3	8.3%
7.9	8.0	8.0	-2.3%
2.2	1.4	1.4	-53.4%
2.7	2.8	2.8	-2.5%

(5) International Markets

	Unit: B¥			
	FY20 Full Year	FY21 Full Year	Change	Change (%)
Revenue	111.1	110.1	-1.0	-0.9%
XTANDI	25.5	32.2	6.7	26.5%
XOSPATA	0.2	0.7	0.5	348.5%
BETMIGA	8.5	8.1	-0.4	-5.0%
Vesicare	3.7	3.7	-0.0	-0.2%
Prograf	31.7	31.7	0.0	0.1%
Harnal	15.1	16.1	1.1	7.1%
MYCAMINE	4.4	6.1	1.8	40.4%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc

Forecasts		Change from FY21	
FY21 Full Year	FY22 Full Year	FY22 Full Year	Change (%)
122.5	118.5	118.5	7.7%
32.6	40.6	40.6	26.1%
0.6	1.9	1.9	173.5%
8.2	8.1	8.1	0.0%
3.6	3.9	3.9	5.1%
33.2	33.5	33.5	5.4%
16.2	17.8	17.8	10.3%
6.1	6.2	6.2	1.1%

9. Consolidated statements of financial position

Unit: B¥

	FY20 End	FY21 End	Change
Assets	2,273.6	2,332.4	58.8
Non-current assets	1,401.0	1,409.0	8.0
Property, plant and equipment	264.6	269.0	4.4
Goodwill	284.0	303.0	19.0
Intangible assets	651.4	623.4	-28.0
Trade and other receivables	33.9	29.8	-4.1
Investments accounted for using equity method	7.1	10.0	2.9
Deferred tax assets	54.2	72.3	18.2
Other financial assets	95.9	91.8	-4.0
Other non-current assets	9.9	9.5	-0.4
Current assets	872.6	923.4	50.8
Inventories	164.1	153.1	-11.0
Trade and other receivables	343.2	382.5	39.3
Income tax receivable	14.0	21.5	7.6
Other financial assets	5.6	21.3	15.7
Other current assets	19.7	29.0	9.3
Cash and cash equivalents	326.1	316.0	-10.1

Unit: B¥

	FY20 End	FY21 End	Change
Equity and Liabilities	2,273.6	2,332.4	58.8
Equity	1,386.1	1,460.3	74.2
Equity attributable to owners of the parent	1,386.1	1,460.3	74.2
Share capital	103.0	103.0	-
Capital surplus	177.8	179.5	1.6
Treasury shares	-15.4	-13.9	1.4
Retained earnings	953.3	944.3	-9.0
Other components of equity	167.4	247.5	80.1
Liabilities	887.5	872.1	-15.4
Non-current liabilities	295.1	184.7	-110.5
Trade and other payables	0.4	0.7	0.3
Deferred tax liabilities	18.2	5.8	-12.3
Retirement benefit liabilities	39.0	37.2	-1.8
Provisions	5.8	5.8	0.0
Other financial liabilities	199.0	95.9	-103.1
Other non-current liabilities	32.8	39.2	6.5
Current liabilities	592.4	687.4	95.0
Trade and other payables	124.8	130.7	6.0
Income tax payable	8.4	32.4	24.0
Provisions	22.2	16.6	-5.6
Other financial liabilities	148.2	185.0	36.8
Other current liabilities	288.9	322.8	33.9

10. Employees

Number of employees

	FY20 End	FY21 End
Total	15,455	14,522

11. Shareholders

	FY20 End	FY21 End
Banks	38.3%	38.4%
Securities	4.3%	4.6%
Other companies	3.1%	3.2%
Foreign companies	45.6%	45.5%
Individuals and others	8.6%	8.2%
Treasury Stock*	0.1%	0.0%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

[For the year ended March 31, 2021]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY21							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	326.1	6.2%	325.5	5.5%	340.6	4.7%	303.9	-1.5%
Cost of sales	62.2	4.3%	62.5	4.4%	69.4	1.7%	58.9	1.0%
Ratio to Revenue	19.1%		19.2%		20.4%		19.4%	
Gross profit	263.9	6.7%	263.0	5.8%	271.3	5.5%	245.0	-2.1%
SG&A expenses	137.1	13.5%	133.4	9.9%	135.9	12.4%	142.4	0.8%
Ratio to Revenue	42.0%		41.0%		39.9%		46.9%	
XTANDI co-promotion fee in the United states	34.5	9.4%	36.6	24.8%	37.6	28.0%	30.6	2.3%
Personnel expenses	49.0	7.3%	47.0	5.5%	47.0	7.8%	48.4	0.0%
Advertising and Sales Promotion and Other	53.6	23.0%	49.8	4.9%	51.3	7.0%	63.4	0.7%
R&D expenses	58.3	1.8%	60.7	11.6%	58.6	2.6%	68.4	22.8%
Ratio to Revenue	17.9%		18.7%		17.2%		22.5%	
Amortisation of intangible assets	6.0	1.8%	6.4	12.7%	7.9	37.0%	8.0	24.2%
Gain on divestiture of intangible assets	-	-	-	-	24.1	-	0.1	-
Share of profit (loss) of investments accounted for using equity method	0.3	-	0.0	-	1.7	-	-1.5	-
Other income	0.4	-82.0%	2.4	-24.6%	3.1	-20.8%	12.7	369.6%
Net foreign exchange gains	0.3	-70.5%	2.0	-	-	-100.0%	7.6	309.5%
Fair value remeasurements on contingent consideration	-	-	0.0	-99.9%	2.2	-	4.8	-
Other expense	27.1	465.2%	10.8	-75.4%	18.6	292.3%	51.1	-30.7%
Impairment losses	26.1	690.7%	0.0	-100.0%	0.7	-68.5%	48.1	-26.0%
Restructuring costs	0.6	-	2.0	116.7%	15.8	713.6%	1.3	-80.5%
Net foreign exchange losses	-	-	-	-100.0%	1.7	-	-	-
Fair value remeasurements on contingent consideration	0.0	-91.4%	8.7	109.5%	0.0	-92.6%	-	-100.0%
Operating profit	36.1	-40.7%	54.1	107.5%	79.2	9.1%	-13.7	-
Ratio to Revenue	11.1%		16.6%		23.3%		-4.5%	
Finance income	1.5	284.3%	0.4	-85.9%	0.4	-86.4%	3.8	-24.7%
Finance expenses	1.7	79.6%	1.3	363.6%	1.3	150.7%	0.7	14.6%
Profit before tax	35.8	-40.5%	53.3	84.6%	78.3	4.2%	-10.5	-
Ratio to Revenue	11.0%		16.4%		23.0%		-3.5%	
Income tax expense	5.1	-47.7%	12.3	91.9%	17.4	15.8%	-2.1	-
Profit	30.7	-39.1%	40.9	82.5%	60.9	1.3%	-8.4	-
Ratio to Revenue	9.4%		12.6%		17.9%		-2.8%	
Comprehensive income	36.2	-34.7%	33.9	49.4%	94.5	21.4%	43.6	70.2%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY21							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	326.1	6.2%	325.5	5.5%	340.6	4.7%	303.9	-1.5%
Cost of sales	62.2	4.3%	62.5	4.4%	69.4	1.7%	58.9	1.0%
Ratio to Revenue	19.1%		19.2%		20.4%		19.4%	
Gross profit	263.9	6.7%	263.0	5.8%	271.3	5.5%	245.0	-2.1%
SG&A expenses	137.1	13.5%	133.4	9.9%	135.9	12.4%	142.4	0.8%
Ratio to Revenue	42.0%		41.0%		39.9%		46.9%	
XTANDI co-promotion fee in the United states	34.5	9.4%	36.6	24.8%	37.6	28.0%	30.6	2.3%
Personnel expenses	49.0	7.3%	47.0	5.5%	47.0	7.8%	48.4	0.0%
Advertising and Sales Promotion and Other	53.6	23.0%	49.8	4.9%	51.3	7.0%	63.4	0.7%
R&D expenses	58.3	1.8%	60.7	11.6%	58.6	2.6%	68.4	22.8%
Ratio to Revenue	17.9%		18.7%		17.2%		22.5%	
Amortisation of intangible assets	6.0	1.8%	6.4	12.7%	7.9	37.0%	8.0	24.2%
Gain on divestiture of intangible assets	-	-	-	-	24.1	-	0.1	-
Share of profit (loss) of investments accounted for using equity method	0.3	-	0.0	-	1.7	-	-1.5	-
Operating profit	62.8	-0.9%	62.5	-6.6%	94.8	29.0%	24.7	-48.1%
Ratio to Revenue	19.3%		19.2%		27.8%		8.1%	
Finance income	1.5	284.3%	0.4	-85.9%	0.4	-86.4%	3.8	-24.7%
Finance expenses	1.7	79.6%	1.3	363.6%	1.3	150.7%	0.7	14.6%
Profit before Tax	62.6	-0.4%	61.7	-11.6%	93.9	23.5%	27.9	-46.6%
Ratio to Revenue	19.2%		18.9%		27.6%		9.2%	
Income tax expense	13.3	23.3%	12.1	-21.9%	22.9	47.8%	7.0	-21.6%
Profit	49.2	-5.3%	49.5	-8.6%	70.9	17.3%	20.9	-51.7%
Ratio to Revenue	15.1%		15.2%		20.8%		6.9%	

3. Revenue by Region

Unit: B¥

		FY21							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		326.1	6.2%	325.5	5.5%	340.6	4.7%	303.9	-1.5%
	Japan	67.5	-13.2%	63.0	-5.2%	72.7	-6.3%	55.5	-3.1%
	Ratio to Revenue	20.7%		19.4%		21.3%		18.3%	
	United States	133.6	14.1%	136.5	14.1%	137.8	15.7%	129.5	10.3%
	Ratio to Revenue	41.0%		41.9%		40.5%		42.6%	
	Established Markets	78.0	21.8%	79.4	6.0%	81.9	3.5%	75.9	1.0%
	Ratio to Revenue	23.9%		24.4%		24.0%		25.0%	
	Greater China	16.4	15.5%	16.6	8.3%	17.3	21.2%	16.0	3.2%
	Ratio to Revenue	5.0%		5.1%		5.1%		5.3%	
	International Markets	27.8	-8.1%	27.5	3.7%	27.7	-10.3%	27.1	15.3%
	Ratio to Revenue	8.5%		8.4%		8.1%		8.9%	
	Others	2.8	-21.9%	2.5	-55.9%	3.3	-28.1%	-0.2	-101.1%
	Ratio to Revenue	0.9%		0.8%		1.0%		-0.1%	

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

4. Investment in Property , Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY21							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Investment in Property , Plant and Equipment									
	Consolidated	5.2	-27.3%	7.8	4.9%	9.3	0.3%	7.8	-20.4%
Depreciation (PP&E)									
	Consolidated	9.9	-0.6%	10.0	-0.1%	10.4	3.5%	9.7	-2.1%
Amortisation of Intangible Assets (incl. software, etc.)									
	Consolidated	8.2	2.6%	9.0	12.7%	11.1	37.4%	11.4	31.6%

- Investment in Property , Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY21							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI		132.9	18.7%	134.7	18.6%	143.9	22.8%	122.7	6.1%
	United States	68.4	9.1%	72.7	24.5%	74.6	26.6%	61.2	4.5%
	ex-US	64.5	31.0%	62.0	12.4%	69.3	18.9%	61.6	7.7%
	Japan	12.0	18.5%	11.5	17.9%	12.9	16.6%	10.7	16.3%
	Established Markets	42.8	36.1%	41.1	9.9%	44.9	12.4%	41.3	1.9%
	Greater China	1.9	165.1%	1.7	11.1%	1.9	97.9%	2.4	45.7%
	International Markets	7.8	12.2%	7.6	18.8%	9.6	52.9%	7.2	23.4%
XOSPATA		8.3	47.7%	8.2	53.0%	9.2	38.4%	8.3	34.5%
	Japan	1.1	6.6%	1.0	19.0%	1.0	-3.5%	0.8	-7.8%
	United States	4.6	26.9%	4.4	21.1%	5.4	25.8%	4.5	14.0%
	Established Markets	2.0	99.4%	2.1	156.3%	2.4	81.8%	2.5	102.7%
	Greater China	0.5	-	0.5	-	0.3	-	0.2	822.1%
	International Markets	0.1	-	0.1	785.7%	0.1	321.1%	0.3	176.8%
PADCEV		4.2	41.9%	4.9	60.8%	5.6	68.1%	7.0	102.2%
	Japan	-	-	-	-	0.5	-	1.2	-
	United States	4.2	41.9%	4.9	60.8%	5.0	50.8%	5.4	54.9%
	Established Markets	-	-	-	-	0.0	-	0.4	-
EVRENZO		0.6	282.9%	0.8	352.1%	0.7	91.3%	0.5	16.2%
	Japan	0.6	282.9%	0.7	288.3%	0.7	88.2%	0.5	19.7%
	Established Markets	-	-	0.1	-	0.0	-	0.0	-
Betanis/Myrabetriq/BETMIGA		44.0	8.8%	40.4	2.2%	42.5	0.5%	45.4	9.9%
	Japan	9.8	16.2%	8.9	8.5%	10.5	4.8%	8.3	-1.4%
	United States	22.8	-0.5%	19.3	-8.9%	19.9	-9.1%	25.2	14.4%
	Established Markets	8.5	29.4%	9.4	21.0%	9.7	27.9%	9.0	13.9%
	Greater China	0.7	56.9%	0.6	23.5%	0.7	15.0%	0.9	44.0%
	International Markets	2.2	5.8%	2.3	15.3%	1.8	-21.7%	1.9	-15.8%
Vesicare		7.4	-4.4%	5.4	-36.6%	5.2	-38.8%	4.2	-39.4%
	Japan	4.6	-7.7%	2.0	-55.3%	2.1	-59.9%	1.4	-64.9%
	United States	0.2	-39.4%	0.7	-46.3%	0.5	67.6%	0.2	-5.2%
	Established Markets	1.4	14.4%	1.5	-6.6%	1.2	-29.0%	1.3	-19.5%
	Greater China	0.3	22.3%	0.2	-10.2%	0.3	-0.4%	0.3	-5.1%
	International Markets	0.9	-3.9%	1.0	6.0%	1.1	8.4%	0.8	-12.4%
Prograf		45.2	-0.3%	47.1	6.4%	48.8	0.2%	44.3	-0.2%
	Japan	10.2	-7.9%	9.4	-5.3%	10.7	-3.5%	7.9	-8.6%
	United States	2.1	-40.8%	2.7	-11.7%	2.8	-1.7%	1.8	-24.3%
	Established Markets	16.2	17.0%	18.2	9.9%	17.5	1.8%	16.0	-3.5%
	Greater China	9.6	22.9%	9.9	17.7%	10.3	20.1%	8.3	-11.5%
	International Markets	7.0	-21.7%	6.9	8.9%	7.6	-16.4%	10.2	39.7%

- Sales of products in Japan are shown in a gross sales basis

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY21							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	12.0	18.5%	11.5	17.9%	12.9	16.6%	10.7	16.3%
XOSPATA	1.1	6.6%	1.0	19.0%	1.0	-3.5%	0.8	-7.8%
PADCEV	-	-	-	-	0.5	-	1.2	-
EVRENZO	0.6	282.9%	0.7	288.3%	0.7	88.2%	0.5	19.7%
Betanis	9.8	16.2%	8.9	8.5%	10.5	4.8%	8.3	-1.4%
Vesicare	4.6	-7.7%	2.0	-55.3%	2.1	-59.9%	1.4	-64.9%
Prograf (Including Gracaptor)	10.2	-7.9%	9.4	-5.3%	10.7	-3.5%	7.9	-8.6%
Harnal	0.7	-20.2%	0.6	-15.1%	0.7	-10.6%	0.5	-8.6%
Funguard	0.4	-70.7%	0.4	-68.3%	0.5	-58.0%	0.3	-32.0%

<Main products>

Suglat [Family]	7.9	10.9%	7.5	11.8%	8.3	7.1%	6.6	3.8%
Sujanu	3.2	13.6%	3.1	15.2%	3.4	6.5%	2.7	5.1%
Repatha	1.5	25.3%	1.4	9.8%	1.6	9.5%	1.3	8.1%
Linzess	1.8	12.9%	1.7	11.7%	2.0	7.9%	1.5	1.7%
BLINCYTO	1.4	17.6%	1.5	52.2%	1.8	50.0%	1.6	41.8%
EVENITY	7.0	1.6%	7.4	28.8%	8.8	39.2%	8.1	40.7%
Smyraf	0.6	179.6%	0.6	52.3%	0.7	22.2%	0.5	-5.5%
Geninax	0.7	15.4%	0.6	19.3%	0.8	-11.1%	0.5	0.1%
Vaccines	0.0	0.0%	2.0	-29.0%	3.2	-36.5%	-0.1	-238.2%
Gonax	1.3	-20.3%	1.3	3.4%	1.3	20.8%	1.1	-1.6%
Cimzia	2.8	12.3%	2.8	14.1%	3.1	12.1%	2.4	5.8%
Myslee	1.8	-11.4%	1.8	-10.7%	1.9	-9.9%	1.5	-8.0%
Total Rx Sales In Japanese market	67.0	-12.9%	62.6	-5.3%	72.0	-5.9%	55.2	-3.0%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M\$

		FY21							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		1,221	12.1%	1,240	10.2%	1,211	6.3%	1,110	0.2%
	XTANDI	625	7.2%	661	20.1%	656	16.4%	522	-5.6%
	XOSPATA	42	24.7%	40	16.9%	48	16.3%	39	3.4%
	PADCEV	38	39.5%	45	55.3%	44	39.0%	46	41.5%
	Myrbetriq	208	-2.2%	175	-12.2%	174	-16.7%	218	4.8%
	Vesicare	2	-40.4%	6	-47.9%	5	50.9%	2	-17.0%
	Prograf	19	-41.8%	24	-14.9%	25	-9.6%	16	-32.1%
	MYCAMINE	14	-40.4%	16	-25.8%	11	-38.3%	7	-65.9%
	Ambisome	30	35.9%	38	29.3%	33	-2.3%	33	18.1%
	CRESEMBA	45	25.8%	49	23.5%	48	8.4%	52	31.6%
	Lexiscan	196	77.1%	186	3.1%	169	2.3%	174	4.7%

(3) Established Markets

Unit: M€

		FY21							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		591	9.4%	612	1.2%	629	-1.1%	582	-1.1%
	XTANDI	325	22.2%	317	4.9%	345	7.4%	316	-0.5%
	XOSPATA	15	79.0%	16	146.7%	18	73.2%	19	97.5%
	PADCEV	-	-	-	-	0	-	3	-
	EVRENZO	-	-	1	-	0	-	0	-
	BETMIGA	65	16.2%	72	15.4%	75	22.4%	69	11.3%
	Vesicare	11	2.7%	12	-11.1%	9	-32.1%	10	-21.2%
	Prograf	123	5.1%	140	4.8%	134	-2.7%	123	-5.6%
	Omnice	17	12.2%	19	12.1%	16	-9.6%	16	1.5%
	MYCAMINE	7	-47.6%	6	-47.7%	5	-54.9%	4	-58.1%

- Established Markets: Europe, Canada, Australia

(4) Greater China

Unit: B¥

		FY21							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		16.4	15.5%	16.6	8.3%	17.3	21.2%	16.0	3.2%
	XTANDI	1.9	165.1%	1.7	11.1%	1.9	97.9%	2.4	45.7%
	XOSPATA	0.5	-	0.5	-	0.3	-	0.2	822.1%
	BETMIGA	0.7	56.9%	0.6	23.5%	0.7	15.0%	0.9	44.0%
	Vesicare	0.3	22.3%	0.2	-10.2%	0.3	-0.4%	0.3	-5.1%
	Prograf	9.6	22.9%	9.9	17.7%	10.3	20.1%	8.3	-11.5%
	Harnal	2.0	-46.8%	2.0	-33.4%	2.1	-3.6%	2.1	9.0%
	MYCAMINE	0.6	25.3%	0.7	1.7%	0.8	28.2%	0.8	20.0%
	Feburic	0.6	9.7%	0.7	15.0%	0.7	-0.4%	0.8	15.6%

- Greater China: China, Hong Kong, Taiwan

(5) International Markets

Unit: B¥

		FY21							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		27.8	-8.1%	27.5	3.7%	27.7	-10.3%	27.1	15.3%
	XTANDI	7.8	12.2%	7.6	18.8%	9.6	52.9%	7.2	23.4%
	XOSPATA	0.1	-	0.1	785.7%	0.1	321.1%	0.3	176.8%
	BETMIGA	2.2	5.8%	2.3	15.3%	1.8	-21.7%	1.9	-15.8%
	Vesicare	0.9	-3.9%	1.0	6.0%	1.1	8.4%	0.8	-12.4%
	Prograf	7.0	-21.7%	6.9	8.9%	7.6	-16.4%	10.2	39.7%
	Harnal	4.3	2.1%	3.8	-2.4%	4.6	30.4%	3.4	0.2%
	MYCAMINE	1.6	64.6%	2.0	97.2%	1.1	-5.0%	1.4	16.4%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Apr 2022

Underlined items indicate changes from the previous announcement in Feb 2022.

XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China P-III	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	P-III		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, platinum-containing chemotherapy and PD-1/L1 inhibitor pretreated	Europe <u>Approved (Apr 2022)</u>	In-house [Co-development with Seagen]	
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		

XTANDI and Strategic products (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
zolibetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
roxadustat ASP1517/FG-4592 (EVRENZO)	Small molecule	HIF-PH inhibitor	Chemotherapy-induced anemia	P-II	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa
fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms associated with menopause	P-III	In-house (Ogeda)	
resamirigene bilparovect AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Feb 2022):

enfortumab vedotin (ASG-22ME): Obtained the approval in Europe in Apr 2022 for locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immuno-oncology	ASP9801	Oncolytic virus	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	WT1 loaded artificial adjuvant vector cell	Acute myeloid leukemia and myelodysplastic syndrome	P-II	RIKEN [Discovered through collaborative research]	
				Solid tumor	P-I		
	ASP0739	Cell therapy (artificial adjuvant vector cells)	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]		
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Ocata Therapeutics)	
Mitochondria Biology	bocidelpar ASP0367/MA-0211	Small molecule	PPARδ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
				Duchenne muscular dystrophy	P-I		
	ASP8731/ML-0207	Small molecule	BACH1 inhibitor	Sickle cell disease	P-I	In-house (Mitobridge)	

Projects with Focus Area approach (2/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
(Other projects with Focus Area approach)	FX-322	Small molecule	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
	ASP3082	Small molecule		Cancer	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** AT132 is also listed in "XTANDI and Strategic products".

Updates from the previous announcement (Feb 2022):

ASP8731/ML-0207: Entered into Phase 1 for sickle cell disease.

ASP3082: Entered into Phase 1 for cancer.

ASP1951/PTZ-522: Discontinued Phase 1 program for cancer.

ASP1128/MA-0217: Discontinued the development for acute kidney injury because Phase 2 study did not meet its primary endpoint.

ASP3772: Discontinued the development for prevention of pneumococcal disease in Phase 2 due to strategic prioritization.

ASP2390: Discontinued Phase 1 program for house dust mite-induced allergic rhinitis.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
			Overactive bladder in pediatric patients	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
ASP8062	Small molecule	GABA _B receptor positive allosteric modulator	Opioid use disorder	P-II	In-house	
			Alcohol use disorder	P-I		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Rx+ Program

As of Apr 2022

Underlined items indicate changes from the previous announcement in Feb 2022.

Sphere (Business area)	Program	Concept	Status *	Partner	Remarks
Chronic disease progression prevention	Game application for exercise support	Smartphone application to support exercise using motion sensing technology for people who needs regular exercise	Under development	BANDAI NAMCO Entertainment	
	Fit-eNce	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise	Under test marketing		
	Fit-eNce Home	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise at home	Under test marketing		
	BlueStar	Digital therapeutics for adults with diabetes	<u>Under clinical trial preparation</u>	Welldoc	
Patient outcome maximization	padexacianinium chloride ASP5354	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.	P-III		

* The list shows the most advanced stage if the stages are different depending on the region.

Updates from the previous announcement (Feb 2022)

BlueStar: Entered into clinical trial preparation phase.